BEIJING--(BUSINESS WIRE)--Oct 26, 2023--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of the Company鈥檚 BTK ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 26, 2023--Foundation Medicine, Inc., today announced its participation in the National Cancer Institute鈥檚 (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 25, 2023--<a ...
CHICAGO--(BUSINESS WIRE)--Oct 25, 2023--<a ...
DUBLIN--(BUSINESS WIRE)--Oct 24, 2023--The <a ...
DUBLIN--(BUSINESS WIRE)--Oct 24, 2023--The <a ...